ClinicalTrials.gov
Cure8 trial brief
The Safety and Efficacy of Good Feeling Power® for IBD Patients
Research and clinical trials
Clinical Trial Phase 1
Adult patients
Clinicians
Researchers
Ulcerative colitis
Crohn's disease
Why This Matters
This trial tests a mushroom-derived dietary supplement in people with mild-to-moderate UC or colonic/ileal Crohn's disease, measuring symptoms, fecal biomarkers, and endoscopic activity—outcomes that matter to patients and clinicians assessing whether a supplement might affect disease.
Who Should Pay Attention
Adult patients with mild-to-moderate UC or colonic/ileal Crohn's disease; clinicians and researchers interested in dietary supplements or early-phase IBD interventions.
Study Snapshot
Story typeClinical Reference
Trial phaseNA
Enrollment36 participants
Study statusCompleted
Source depthTrial registry record
What To Know
The study enrolled up to 36 adults and gave the supplement orally to all participants; there was no placebo or comparator arm listed.
Primary outcomes included symptom scores (Simple Clinical Colitis Activity Index for UC and Harvey‑Bradshaw Index for CD), fecal biomarkers (calprotectin, fecal IgA, fecal hemoglobin), and endoscopic parameters (Mayo Endoscopic Score) assessed from baseline to day 180.
The record is a trial registry entry (ClinicalTrials.gov) with basic design, eligibility, and outcome measures but does not provide results in the posted text. Because it is an open‑label pilot, findings—if posted elsewhere—would need cautious interpretation compared with randomized, controlled trials.
Keep In Mind
The registry entry provides protocol details and primary outcomes but does not include results in the supplied text. The study is open‑label and small (planned n=36), so any efficacy signals would need confirmation in larger, controlled trials.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorGood Feeling Products GmbH
Trial IDNCT07766733
Study typeInterventional
Trial phaseNA
Enrollment36 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedAug 14, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
Patients on anti-TNF biologics often seek safe ways to support gut microbial health. This trial tests a prebiotic supplement (2'-FL) for safety and whether it increases beneficial bacteria and butyrate in young people...
Engineered perturbations to define B cell entry, competition, and function in intestinal immunity and inflammation
Researchers are exploring a way to deliver biologic drugs directly in the gut using engineered B cells that become long-lived plasma cells. If successful, this could allow sustained, localized anti-inflammatory protein...
Understanding role of microbiota in Crohn's disease, ulcerative colitis
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...